Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06630208
Starting soon Not applicable

Effectiveness of Myofascial Release in Patients With Chronic Post Sternotomy Pain Syndrome

NCT06630208 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Not applicable
Started
2024-12-15
Last updated
2024-10-08

Condition(s) studied

Chronic Postsurgical Pain

Investigational drug(s) / intervention(s)

Myofascial releaseBreathing exercisesPharmacological treatment

Myofascial release: The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.

Breathing exercises: Following the 3 phases of myofascial release, breathing exercises will be done for patients.

Pharmacological treatment: Patients will take pharmacological treatment prescribed by the cardiologist.

Study summary

The main aim of this study is to investigate the effectiveness of Myofascial release in patients with chronic sternotomy pain.

Eligibility

Sex
ALL
Min age
55 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Chronic Post-sternotomy pain (CPSP), defined as discomfort at the thorax after cardiac surgery, persisting for at least 2 months, and without apparent cause (I.e., such as infection or the underlying disease that motivated the surgery). * Age between 55 to 65 years old. * All patients will be under full medical supervision. * Adherence to informed consent. * Cardiac sternotomy intervention Exclusion Criteria: * Neuromuscular disorders. * Any Active hemorrhage. * The presence of an unstable cardiac, pulmonary or cerebral pathology. * Poor cognition and mentality. * Patients with active contagious skin conditions * Any Cardiopulmonary problems (eg. Uncontrolled hypertension, Heart Failure, Arrhythmia) * Patients with malignancy. * Any acute viral infection. * Patients with ascites or end-stage liver or kidney failure. * Patients will participate in other physiotherapy programs rather than the prescribed protocol. * Chest infection in last 3 months. * Patients with musculoskeletal problems like any bone fracture * Osteoporotic patients. * Any recent open wound in the chest are. * Hemodynamic instability.

Primary outcome measure(s)

  • Visual analog scale (VAS) — 5 days
    Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm).
  • Upper chest expansion — 5 days
    It will be obtained by subtracting the inspiratory diameter from the expiratory diameter, according to the designated anatomical markers.
  • Lower chest expansion — 5 days
    It will be obtained by subtracting the inspiratory diameter from the expiratory diameter, according to the designated anatomical markers.
  • Pressure pain threshold — 5 days
    Pressure algometers are useful for quantifying the pressure pain thresholds of muscles. The pressure pain threshold of a patient is judged to be abnormal when the pressure pain threshold was lower than the normal value or if the pressure pain threshold of a certain site was lower than that of the opposite site by at least 2 kg/cm2, or if it was less than 3 kg/cm2.

Trial sites (1)

FacilityCityRegionStatus
Cairo University Giza Egypt

More Cairo University trials in Egypt

The Link Between Periodontitis, Smoking and Oral Cancer Starting soon
Treating Intrabony Defect With MINST VS MINST Extended PRF Recruiting
Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain Recruiting
Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure Starting soon
Preparation Time Of Bioflx Crowns Compared To Zirconia Crowns On Primary Molars Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06630208 on ClinicalTrials.gov ↗ ← All trials in Egypt